CIVILICA We Respect the Science
Publisher of Iranian Journals and Conference Proceedings
Paper
title

Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment

Credit to Download: 0 | Page Numbers 2 | Abstract Views: 130
Year: 2016
COI code: IPMCMED01_059
Paper Language: English

How to Download This Paper

For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.

Authors Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment

  Fatemeh Khatami - Chronic Disease Research Center, Endocrinology and Metabolism Population Science Institute, Tehran University of Medical Sciences, Tehran, IRAN
  Ramin Heshmat - Chronic Disease Research Center, Endocrinology and Metabolism Population Science Institute, Tehran University of Medical Sciences, Tehran, IRAN
  Seyed Mohammad Tavangar - Department of Pathology, Doctor Shariati Hospital, Tehran University of Medical Sciences, Iran
  Bagher Larijani - Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Iran

Abstract:

Common medical treatments have some difficulties for cancer therapy in a desire way because of resistance to current therapeutics. Personalized cancer therapy aims to understand the unique properties and dynamics of each patient’s cancer in order to provide the most rational and appropriate therapy. It is still under the debate that circulating tumor markers will take the place of standard tissue biopsy or will support it to guide us to the more effective interventions According to American Cancer Society 62,450 people diagnosed with thyroid cancer in 2015 and 1950 deaths will result from the disease. In spite of good prognosis of differentiated thyroid carcinoma (DTC), about five to ten percent of patients will develop metastasis and fail torespond to radioactive iodine (RAI), and other traditional therapies. The lack of effectivetherapies for DTC, resistant to radioiodine and traditional therapies is now being overcome by the development of targeted novel compounds.The published result related to a phase II clinical study in Philadelphia illustrated treating metastatic thyroid cancer patients with the targeted therapy Vemurafenib to establish the activity of Vemurafenib in patients with BRAFV600E-positive papillary thyroid. The large-scale drug screening that incorporates genomic and gene expression data is another breakthrough to identify drug response biomarkers that could inform optimal application of cancer drugs. It is a commonknowledge that a small piece of a tumor receiving after tissue biopsy doesn’t represent the whole tumor, let alone metastases. Liquid biopsy, which is a diagnostic concept, opens a newperspective for real time monitoring of cancer open a new perspective for tumor evaluation.Liquid biopsy is defined as circulating tumor cells (CTCs) and fragments of circulating tumorDNA (ctDNA) shed into the bloodstream from primary and metastatic tumor deposits. Using ofctDNA is superior as a non-invasive and cost effective solution to identify reliable biomarkers for measuring tumor growth, metastasis and response to treatments. Liquid biopsies could be used to guide cancer treatment strategy and perhaps even screen for tumors that are not yet visible on imaging. Take advances in molecular genetic technology into consideration, evaluation and characterization of circulating tumor markers can be the best alternative for realtime tumor tracking. In the near future tissue biopsy will be replaced by liquid biopsy and now is the exact time to focus on CTCs and ctDNA as a circulating tumor biomarker specifically in personalization of cancer treatment.

Keywords:

BRAF mutation, Thyroid Cancer, Personalized Medicine

Perma Link

https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_059.html
COI code: IPMCMED01_059

how to cite to this paper:

If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Khatami, Fatemeh; Ramin Heshmat; Seyed Mohammad Tavangar & Bagher Larijani, 2016, Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment, First Personal Medical Congress, تهران, دانشگاه علوم پزشكي ايران - پژوهشكده ملي مهندسي ژنتيك و زيست فناوري ايران، مركز همكاري هاي فناوري و نوآوري هاي رياست جمهوري, https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_059.htmlInside the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Khatami, Fatemeh; Ramin Heshmat; Seyed Mohammad Tavangar & Bagher Larijani, 2016)
Second and more: (Khatami; Heshmat; Tavangar & Larijani, 2016)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)

Scientometrics

The University/Research Center Information:
Type: Medical University
Paper No.: 6412
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.

Research Info Management

Export Citation info of this paper to research management softwares

New Related Papers

Iran Scientific Advertisment Netword

Share this paper

WHAT IS COI?

COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.